Conditional survival predictionsafter nephrectomy for renal cell carcinoma

Autor: Karakiewicz, Pi, Suardi, N, Capitanio, U, Isbarn, H, Jeldres, C, Perrotte, P, Sun, M, Ficarra, Vincenzo, Zigeuner, R, Tostain, J, Mejean, A, Cindolo, L, Pantuck, Aj, Belldegrun, As, Zini, L, DE LA TAILLE, A, Chautard, D, Descotes, Jl, Shariat, Sf, Valeri, A, Mulders, Pf, Lang, H, Lechevallier, E, Patard, Jj

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3657::ccfad56d393e83765b04ca7efd56466a
http://hdl.handle.net/11577/2377668

Angiogeneseremmers voor de systemische behandeling van gemetastaseerd niercelcarcinoom: sunitinib, sorafenib, bevacizumab en temsirolimus

Autor: de Mulder, PH, Haanen, John B., Sleijfer, Stefan, Kruit, Wim H., Gietema, Jourik A., Richel, DJ, Groenewegen, G., Voest, EE, van den Eertwegh, AJM, Osanto, S, Jansen, RLH, Mulders, PF

Publikováno v: Nederlands Tijdschrift voor Geneeskunde, 152, 371-375. NLM (Medline)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::2ff99d4190e2659521cf624ffc0c341f
https://research.rug.nl/en/publications/337c221c-07e6-4c5e-a100-df98a7b797e4

Renal Cell Carcinoma with Nodal Metastases in the Absence of Distant MetastaticDisease: Prognostic Indicators of Disease-Specific Survival

Autor: Karakiewicz, Pi, Trinh, Qd, Bhojani, N, Bensalah, K, Salomon, L, DE LA TAILLE, A, Tostain, J, Cindolo, L, Altieri, V, Ficarra, Vincenzo, Schips, L, Zigeuner, R, Mulders, Pf, Valeri, A, Descotes, Jl, Mejean, A, Patard, Jj

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3657::031d7de3e9333ebd5703a2d28ecdf9ff
http://hdl.handle.net/11577/1773592

Multi-institutional validation of a new renal cancer-specific survival nomogram.

Autor: Karakiewicz PI, Briganti A, Chun FK, Trinh QD, Perrotte P, Ficarra V, Cindolo L, De la Taille A, Tostain J, Mulders PF, Salomon L, Zigeuner R, Prayer-Galetti T, Chautard D, Valeri A, Lechevallier E, Descotes JL, Lang H, Mejean A, Patard JJ

Publikováno v: Journal of Clinical Oncology; 4/10/2007, Vol. 25 Issue 11, p1316-1322, 7p

Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.

Autor: Gore ME (AUTHOR), Griffin CL (AUTHOR), Hancock B (AUTHOR), Patel PM (AUTHOR), Pyle L (AUTHOR), Aitchison M (AUTHOR), James N (AUTHOR), Oliver RT (AUTHOR), Mardiak J (AUTHOR), Hussain T (AUTHOR), Sylvester R (AUTHOR), Parmar MK (AUTHOR), Royston P (AUTHOR), Mulders PF (AUTHOR), Gore, Martin E¹ (AUTHOR), Griffin, Clare L (AUTHOR), Hancock, Barry (AUTHOR), Patel, Poulam M (AUTHOR), Pyle, Lynda (AUTHOR), Aitchison, Michael (AUTHOR)

Publikováno v: Lancet. 2/20/2010, Vol. 375 Issue 9715, p641-648. 8p.